Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia

National Medical Journal of China

Volumn 87, Issue 20, 2007, Pages 1389-1393

  Qin, Tie Jun ^a   Mi, Ying Chang ^a   Feng, Si Zhou ^a   Li, Da Peng ^a   Wei, Jia Lin ^a   Yang, Dong Lin ^a   Han, Ming Zhe ^a   Wang, Jian Xiang ^a   Bian, Shou Geng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Infection; Leukemia; Neutropenia; Quinolones

Indexed keywords

ANTIBIOTIC AGENT; EXTENDED SPECTRUM BETA LACTAMASE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; ESCHERICHIA COLI; FEVER; GASTROINTESTINAL INFECTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; RETROSPECTIVE STUDY; SEPTICEMIA; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIA; BACTERIAL INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; LEUKEMIA; MALE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; RETROSPECTIVE STUDIES;

EID: 34447539556     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 2002, 34: 730-751.
2. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Ercherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis, 2005, 24: 111-118.
3. Chinese source.
4. Chinese source.
5. Chinese source.
6. Chinese source.
7. Chinese source.
8. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis, 2006, 43: 447-459.